NYVAC-Pf7: A poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

Infection and Immunity

Volumn 64, Issue 9, 1996, Pages 3833-3844

  Tine, John A ^a   Lanar, David E ^b   Smith, Darlene M ^a   Wellde, Bruce T ^b   Schultheiss, Peter ^b   Ware, Lisa A ^b   Kauffman, Elizabeth B ^a   Wirtz, Robert A ^b   De Taisne, Charles ^c   Hui, George S N ^d   Chang, Sandra P ^d   Church, Preston ^e   Hollingdale, Michael R ^f   Kaslow, David C ^g   Hoffman, Stephen ^e   Guito, Kenneth P ^h   Ripley Ballou, W ^b   Sadoff, Jerald C ^b   Paoletti, Enzo ^a  

^a Virogenetics Corporation   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Pasteur Merieux Serums et Vaccins   (France)

^d UNIVERSITY OF HAWAII   (United States)

^e NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h Connaught Laboratories Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; NYVAC PF7; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; INFECTION PREVENTION; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RHESUS MONKEY; VACCINIA VIRUS;

EID: 0003677588     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.9.3833-3844.1996     Document Type: Article

References (97)

1. + cytotoxic T cells. J. Exp. Med. 172:1083-1090.
2. Ballou, W. R., S. L. Huffman, J. A. Sherwood, M. R. Hollingdale, F. A. Neva, W. T. Hockmeyer, D.M. Gordon, I. Schneider, R. A. Wirft, J. F. Young, G. F. Wasserman, P. Reeve, C. L. Diggs, and J. D. Chulay. 1987. Safety and efficacy of a recorabinant DNA Plasmodium falciparum sporozoite vaccine. Lancet i:1277-1281.
3. Barr, P. J., K. M. Green, H. L. Gibson, I. C. Bathurst, I. A. Quakyi, and D. C. Kaslow. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174:1203-1208.
4. Brochier, B., M. P. Kieny, F. Costy, P. Coppens, B. Bauduin, J. P. Lecocq, B. Langnet, G. Chappuis, P. Desmettre, K. Aflademanyo, R. Libois, and P.-P. Pastoret. 1991. Large-scale eradication of rabies using recombinant vacciniarabies vaccine. Nature (London) 354:520-522.
5. Brockmeier, S. L., K. M. Lager, J. Tartaglia, M. Riviere, E. Paoletti, and W. L. Mengeling. 1993. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet. Microbiol. 38:41-58.
6. Burkot, T. R., Z. W. Da, H. M. Geysen, R. A. Wirtz, and A. Saul. 1991. Fine specificities of monoclonal antibodies against the Plasmodium falciparum circumsporozoite protein: recognition of both repetitive and non-repetitive regions. Parasite Immunol. 13:161-170.
7. Caspers, P., R. Gentz, H. Matile, J. R. Pink, and F. Sinigaglia. 1989. The circumsporozoite gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials. Mol. Biochem. Parasitol. 35:185-190.
8. Chakrabarti, S., M. Robert-Guroff, F. Wong-Staal, R. C. Gallo, and B. Moss. 1986. Expression of the HTLV III envelope gene by a recombinant vaccinia virus. Nature (London) 320:535-537.
9. Chang, S. P., G. S. N. Hui, A. Kato, and W. A. Siddiqui. 1989. Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 86:6343-6347.
10. Chang, S. P., K. J. Kramer, K. M. Yamaga, A. Kato, S. E. Case, and W. A. Siddiqui. 1988. Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp195) of the Uganda-Palo Alto isolate. Exp. Parasitol. 67:1-11.
11. Collins, W. E., D. Pye, P. E. Crewther, K. L. Vandenberg, G. G. Galland, A. J. Sulzer, D. J. Kemp, S. J. Edwards, R. L. Coppel, J. S. Sullivan, C. L. Morris, and R. F. Anders. 1994. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51:711-719.
12. Coupar, B. E. H., M. E. Andrew, G. W. Both, and D. B. Boyle. 1986. Temporal regulation of influenza hemaglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 16: 1479-1487.
13. Cox, W. I., J. Tartaglia, and E. Paoletti. 1992. Poxvirus recombinants as live vaccines, p. 123-162. In M. M. Binns and G. L. Smith (ed.), Recombinant poxviruses. CRC Press, Inc., Boca Raton, Fla.
14. Cox, W. I., J. Tartaglia, and E. Paoletti. 1993. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195:845-850.
15. Cremer, K. J., M. Mackett, C. Wohlenberg, A. L. Notkins, and B. Moss. 1985. Vaccinia virus recombinant expressing herpes simplex virus type I glycoprotein D prevents latent herpes in mice. Science 228:737-740.
16. Deans, J. A., A. M. Knight, W. C. Jean, A. P. Waters, S. Cohen, and G. H. Mitchell. 1988. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol. 10:535-552.
17. Delplace, P., A. Bhatia, M. Cagnard, D. Camus, G. Colombet, A. Debrabant, J.-F. Dubremetz, N. Dubreuil, G. Prensier, B. Fortier, A. Haq, J. Weber, and A. Vernes. 1988. Protein p126: a parasitophorous vacuole antigen associated with the release of Plasmodium falciparum merozoites. Biol. Cell 64:215-221.
18. Delplacc, P., B. Fortier, G. Tronchin, J. F. Dubremetz, and A. Vernes. 1987. Localization, biosynthesis, processing, and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium falciparum. Mol. Biochem. Parasitol. 23:193-201.
19. Earl, P. L., A. W. Hügin, and B. Moss. 1990. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64:2448-2451.
20. Enders, B., E. Hundt, and B. Knapp. 1992. Strategies for the development of an antimalarial vaccine. Vaccine 10:920-927.
21. Etlinger, H. M., P. Caspers, H. Matile, H.-J. Schoenfeld, D. Stueber, and B. Takacs. 1991. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infect. Immun. 59:3498-3503.
22. 21a.Gettig, R., and E. Paoletti. Unpublished data.
23. Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-266.
24. Good, M. F., A. Saul, and P. M. Graves. 1992. Malaria vaccines, p. 69-98. in R. W. Ellis (ed.), Vaccines: new approaches to immunological problems. Butterworth-Heinemann, Boston.
25. Gordon, D. M. 1990. Malaria vaccines. Infect. Dis. Clin. N. Am. 4:299-313.
26. Guerin-Marchand, C., P. Druilhe, B. Galey, A. Londono, J. Patarapotikul, R. L. Beaudoin, C. Dubeaux, A. Tartar, O. Mercereau-Puijalon, and G. Langsley. 1987. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature (London) 329:164-167.
27. Guo, P., S. Goebel, M. E. Perkus, J. Taylor, E. Norton, G. Allen, B. Languet, P. Desmettre, and E. Paoletti. 1990. Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity. J. Virol. 64:2399-2406.
28. Hall, R., J. E. Hyde, M. Goman, D. L. Simmons, I. A. Hope, M. Mackay, J. Scaife, B. Merkli, R. Richte, and J. Stocker. 1984. Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria. Nature (London) 311:379-382.
29. Herrera, M. A-, F. Rosero, S. Herrera, P. Caspers, D. Rotmann, F. Sinigaglia, and U. Certa. 1992. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect. Immun. 60:154-158.
30. Herrera, S., M. A. Herrerra, B. L. Perlaza, Y. Burk, P. Caspers, H. Döbeli, D. Rotmann, and U. Certa. 1990. Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins, Proc. Natl. Acad. Sci. USA 87:4017-4021.
31. Herrington, D. A., D. F. Clyde, G. Losonsky, M. Cortesia, J. R. Murphy, J. Davis, S. Baqar, A. M. Felix, E. P. Heimer, D. Gillessen, E. Nardin, R. S. Nussenzweig, M. R. Hollingdale, and M. M. Levine. 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (London) 328:257-259.
32. Hill, A. V. S., J. Elvin, A. C. Willis, M. Aidoo, C. E. M. Allsopp, F. M. Golch, X. M. Gao, M. Takiguchi, B. M. Greenwood, A. R. M. Townsend, A. J. McMichael, and H. C. Whittle. 1992. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature (London) 360:434-439.
33. 31a.Hoffman, S., et al. Unpublished data.
34. Holder, A. A., R. R. Freeman, and S. C. Nichols. 1988. Immunization against Plasmodium falciparum with recombinant polypeptides produced in Escherichia coli. Parasite Immunol. 10:607-617.
35. Hollingdale, M. R., M. Aikawa, C. T. Atkinson, W. R. Ballou, G. Chen, J. Li, J. F. G. M. Meis, B. Sina, C. Wright, and J. Zhu. 1990. Non-CS preerythrocytic protective antigens. Immunol. Lett. 25:71-76.
36. Hu, S. L., S. G. Kosowski, and J. M. Dalrymple. 1986. Expression of the AIDs virus envelope gene in recombinant vaccinia viruses. Nature (London) 320:537-540.
37. Inselburg, J., I. C. Bathurst, J. Kansopon, G. L. Barchfeld, P. J. Barr, and R. N. Rossan. 1993. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity. Infect. Immun. 61:2041-2047.
38. Inselburg, J., I. C. Bathurst, J. Kansopon, P. J. Barr, and R. Rossan. 1993. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infect. Immun. 61:2048-2052.
39. Inselburg, J., D. J. Bzik, W.-B. Li, K. M. Green, J. Kansopon, B. K. Hahm, I. C. Bathurst, P. J. Barr, and R. N. Rossan. 1991. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum. Infect. Immun. 59:1247-1250.
40. Kaslow, D. C., S. N. Isaacs, I. A. Quakyi, R W. Gwadz, B. Moss, and D. B. Keister. 1991. Induction of Plasmodium falciparum transmission blocking antibodies by recombinant vaccinia virus. Science 252:1310-1313.
41. Kaslow, D. C., I. A. Quakyi, C. Syin, M. G. Raum, D. B. Keister, J. E. Coligan, T. F. McCutchan, and L. H. Miller. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature (London) 333:74-76.
42. Khusmith, S., Y. Charoenvit, S. Kumar, M. Sedegah, R. L. Beaudoin, and S. L. Hoffman. 1991. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 252:715-718.
43. Klotz, F. W., T. J. Hadley, M. Aikawa, J. Leech, R. J. Howard, and L. H. Miller. 1989. A 60-kDa Plasmodium falciparum protein at the moving junction formed between merozoite and erythrocyte during invasion. Mol. Biochem. Parasitol. 36:177-185.
44. Knapp, B., A. Shaw, E. Hundt, B. Enders, and H. A. Kupper. 1988. A histidine alanine rich recombinant antigen protects Aotus monkeys from P. falciparum infection. Behring Inst. Mitt. 82:349-359.
45. Konishi, E., S. Pincus, E. Paoletti, R. E. Shops, T. Burrage, and P. W. Mason. 1992. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188:714-720.
46. Kumar, S., A. Yadava, D. B. Keister, J. H. Tian, M. Ohl, K. A. Perdue-Greenfteld, L. H. Miller, and D. C. Kaslow. 1995. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in aotus monkeys. Mol. Med. 3:325-332.
47. Lanar, D. E., J. A. Tine, C. de Taisne, M. C. Seguin, W. I. Cox, J. P. Winslow, L. A. Ware, E. B. Kanffman, D. Gordon, W. R. Ballou, E. Paoletti, and J. C. Sadoff. 1996. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect. Immuno 64:1666-1671.
48. + T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90:5214-5218.
49. Lyon, J. A., J. D. Haynes, C. L. Diggs, J. D. Chulay, C. G. Haidaris, and J. Pratt-Rossiter. 1987 Monoclonal anlibody characterization of the 195-kilodalton major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. J. Immunol. 138:895-901.
50. Mackett, M., and J. R. Arrand. 1985. Recombinant vaccinia virus induces neutralizing antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J. 4:3229-3234.
51. Mason, P. W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti. 1991. Japanese encephalitis virus-vaccinia recombinants produce paniculate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 180:294-305.
52. Miller, L. H., T. Roberts, M. Shahabuddin, and T. F. McCutchan. 1993. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol. Biochem. Parasitol. 59:1-14.
53. Narum, D. L., and A. W. Thomas. 1994. Differential localization of full-length and processed forms of PF83/AM A-1, an apical membrane antigen of Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 67:59-68.
54. Noya, G. O., Y. G. Berti, B. A. de Noya, R. Borges, N. Zerpa, J. D. Urbáez, A. Madonna, E. Garrido, M. A. Jimenéz, R. E. Borges, P. Garcia, I. Reyes, W. Prieto, C. Colmenares, R. Pab́n, T. Barraez, L. G. de Caceres, N. Godoy, and R. Sifantes. 1994. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J. Infect. Dis. 170:396-402.
55. Nussenzweig, V., and R. S. Nussenzweig. 1989. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45:283-334.
56. Ontario Department of Health. 1968. Laboratory manual in virology. Ontario Department of Health, Ontario, Canada.
57. Panicali, D., S. W. Davis, R. L. Weinberg, and E. Paoletti. 1983. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 80:5364-5368.
58. Paoletli, E., B. R. Lipinskas, C. Samsonoff, S. Mercer, and D. Panicali. 1984. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc. Natl. Acad. Sci. USA 81:193-197.
59. Patarroyo, M. E., P. Romero, M. L. Torres, P. Clavijo, A. Moreno, A. Martínez, R. Rodríguez, F. Guzman, and E. Cabezas. 1987. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature (London) 328:629-632.
60. Perkus, M. E., E. B. Kauffman, J. Taylor, S. Mercer, D. Smith, J. Vander-Hoeven, and E. Paoletti. 1993. Methodology of using vaccinia virus to express foreign genes in tissue culture. J. Tissue Cult. Methods 15:72-81.
61. Perkus, M. E., K. Limbach, and E. Paoletti. 1989. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J. Virol. 63:3829-3836.
62. Perkus, M. E., A. Piccini, B. R. Lipinskas, and E. Paoletti. 1985. Recombinant vaccinia virus: immunization against multiple pathogens. Science 229: 981-984.
63. Perrin, L. H., B. Merkli, M. Loche, C. Chizzolini, J. Smart, and R. Richle. 1984. Antimalarial immunity in Samin monkeys. Immunization with surface components of asexual blood stages. J. Exp. Med. 160:441-451.
64. Phillips, R. S. 1992. Vaccination against malaria. Immunobiology 184:240-262.
65. Potocnjak, P., N. Yoshida, R. S. Nussenzweig, and V. Nussenzweig. 1980. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151:1504-1513.
66. Pye, D., S. J. Edwards, R. F. Anders, C. M. O'Brien, P. Franchina, L. N. Corcoran, C. Monger, M. G. Peterson, K. L. Vandenberg, J. A. Smythe, S. R. Westley, R. L. Coppel, T. L. Webster, D. J. Kemp, A. W. Hampson, and C. J. Langford. 1991. Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria. Infect. Immun. 59:2403-2411.
67. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
68. Rogers, W. O., A. Malik, S. Mellouk, K. Nakamura, M. D. Rogers, A. Szarfman, D. M. Gordon, A. K. Nussler, M. Aikawa, and S. L. Huffman. 1992. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc. Natl. Acad. Sci. USA 89:9176-9180.
69. Sadoff, J. C., W. R. Ballou, L. S. Baron, W. R. Majarian, R. N. Brey, W. T. Hockmeyer, J. F. Young, S. J. Cryz, J. Ou, G. H. Lowell, and J. D. Chulay. 1988. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240:336-338.
70. Satchidanandam, V., F. Zavala, and B. Moss. 1991. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol. Biochem. Parasitol. 48:89-100.
71. Schmitt, J. F. C., and H. G. Stunnenberg. 1988. Sequence and transcriptional analysis of the vaccinia virus HindIII I fragment. J. Virol. 62:1889-1897.
72. Schödel, F., R. Wirtz, D. Peterson, J. Hughes, R. Warren, J. Sadoff, and D. Milich. 1994. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med. 180:1037-1046.
73. Sedegah, M., R. L. Beaudoin, P. de la Vega, M. F. Leef, M. A. Ozcel, E. Jones, Y. Charoenvit, L. F. Yuan, M. Gross, W. R. Majarian, F. A. Robey, W. Weiss, and S. L. Huffman. 1988. Use of a vaccinia construct expressing the circumsporozoite protein in the analysis of protective immunity to Plasmodium yoelii, p. 295-300. In L. Lasky (ed.), UCLA symposia on molecular and cellular biology, new series, vol. 84. Technological advances in vaccine development. Alan R. Liss, Inc., New York.
74. Sedegah, M., R. Hedstrom, P. Hobart, and S. L. Huffman. 1994. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci. USA 91:9866-9870.
75. Siddiqui, W. A., and L. Q. Tam. 1988. Review of vaccine trials in nonhuman primates, p. 28-30. In Exocrythrocytic and asexual blood-stage antigens of human malaria parasites: report of the tenth meeting of the Scientific Working Group on the Immunology of Malaria. TDR/IMMAL/SWG(10)/88.3. World Health Organization, Geneva.
76. Siddiqui, W. A., L. Q. Tara, K. J. Kramer, G. S. N. Hui, S. E. Case, K. M. Yamaga, S. P. Chang, E. B. T. Chan, and S.-C. Kan. 1987. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. USA 84:3014-3018.
77. Smith, G. L., B. R. Murphy, and B. Moss. 1983. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc. Natl. Acad. Sci. USA 80:7155-7159.
78. Sturchler, D. 1989. How much malaria is there worldwide? Parasitol. Today 5:39-40.
79. Szarfman, A., J. A. Lyon, D. Walliker, I. Quakyi, R. J. Howard, S. Suns, W. R. Ballou, K. Esser, W. T. London, R. A. Wirtz, and R. Carter. 1988. Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages. Parasite Immunol. 10: 339-351.
80. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, J. VanderHoeven, B. Meignier, M. Riviere, B. Languet, and E. Paoletti. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232.
81. Tartaglia, J., S. Pincus, and E. Paoletti. 1990. Poxvirus-based vectors as vaccine candidates. Crit. Rev. Immunol. 10:13-30.
82. Taylor, J., J. Tartaglia, T. Moran, R. G. Webster, J.-F. Bouquet, F. W. Quimby, D. Holmes, E. Laplace, T. Mickle, and E. Paoletti. 1992. The role of poxvirus vectors in influenza vaccine development, p. 311-335. In Proceedings of the Third International Symposium on Avian Influenza, 1992. University of Wisconsin, Madison.
83. Thomas, A. W., A. P. Waters, and D. Carr. 1990. Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum. Mol. Biochem. Parasitol. 42:285-288.
84. 81a.Tine, J. A., D. C. Kaslow, and E. Paoletti. Unpublished data.
85. 81b.Tine, J. A., S. Davis, and E. Paoletti. Unpublished data.
86. 81c.Tine, J. A., D. M. Smith, E. B. Kauffman, and E. Paoletti. Unpublished data.
87. Tine, J. A., V. Conseil, P. Delplace, C. de Taisne, D. Camus, and E. Paoletti. 1993. Immunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus. Infect. Immun. 61:3933-3941.
88. Valero, M. V., L. R. Amador, C. Galindo, J. Figueroa, M. S. Hello, L. A. Murillo, A. L. Mora, G. Patarroyo, C. L. Rocha, M. Rojas, J. J. Aponte, L. E. Sarmiento, D. M. Lozada, C. G. Coronell, N. M. Ortega, J. E. Rosas, P. L. Alonso, and M. E. Patarroyo. 1993. Vaccination with SPf66, a chemically synthesized vaccine, against Plasmodium falciparum in Columbia. Lancet 341:705-710.
89. Vos, J. C., and H. G. Stunnenberg. 1988. Derepression of a novel class of vaccinia virus genes upon DNA replication. EMBO J. 7:3487-3492.
90. Wachsman, M., L. Aurelian, C. C. Smith, B. R. Lipinskas, M. E. Perkus, and E. Paoletti. 1987. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J. Infect. Dis. 155:1188-1197.
91. Wachsman, M., J. H. Luo, L. Aurelian, M. E. Perkus, and E. Paoletti. 1989. Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity. J. Gen. Virol. 70:2513-2520.
92. Wirtz, R. A., W. R. Ballou, I. Schneider, L. Chedid, M. J. Gross, J. F. Young, M. Hollingdale, C. L. Diggs, and W. T. Hockmeyer. 1987. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp. Parasitol. 63:166-172.
93. Yewdell, J. W., J. R. Bennink, G. L. Smith, and B. Moss. 1985. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza Aviruscytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 82:1785-1789.
94. Young, J. F., W. T. Hockmeyer, M. Gross, W. R. Ballou, R. A. Wirtz, J. H. Trosper, R. L. Beaudoin, M. R. Hollingdale, L. H. Miller, C. L. Diggs, and M. Rosenberg. 1985. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science 228:958-962.
95. Yuen, L., and B. Moss. 1987. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA 84:6417-6421.
96. Zarling, J. M., W. Morton, P. A. Moran, J. McClure, S. G. Kosowski, and S.-L. Hu. 1987. T-cell responses to human AIDs virus in macaques immunized with recombinant vaccinia viruses. Nature (London) 323:344-346.
97. Zhu, J., and M. R. Hollingdale. 1991. Structure of Plasmodium falciparum liver stage antigen-1. Mol. Biochem. Parasitol. 48:223-226.